We are Alzheimer Europe
Alzheimer Europe is the umbrella organisation of 41 national Alzheimer's associations from 37 European countries.
Our mission is to change perceptions, policy and practice in order to improve the lives of people affected by dementia. We are a non-profit non-governmental organisation (NGO) and will achieve our mission by providing a voice to people with dementia and their carers, making dementia a European priority, changing perceptions and combating stigma, raising awareness of brain health and prevention, strengthening the European dementia movement and supporting dementia research.
News
Our work
Recent tweets
Closing our final Company Round Table of 2022, our Director @JeanGeorgesAE gives our sponsors and members an update on our activities in 2022-2023 https://t.co/pHgXYeAzID
Our second speaker at this afternoon's Company Round Table meeting is Policy Officer @OwenMiller1991 who is sharing details about our upcoming 2022 Yearbook, which is focusing on employment, social protection and dementia. https://t.co/CXhfefYXwz
At our Company Round Table meeting this afternoon, Project Officer @CindyBirck updates participants on recent clinical trial developments and on our Clinical Trial Watch. See our website for more info on this resource:
https://t.co/6EtIsJDDLu https://t.co/4oJgtxcY4d
Many thanks to @biogen for continuing to support our activities! Biogen has opted for bronze level sponsorship of our public affairs activities in 2023.
Read more about our sponsorship opportunities, here: https://t.co/nIVsaD5eKx https://t.co/ilHwZVaEjE
A big thank you to @Roche for continuing to support our activities! Roche has opted for gold sponsorship of our activities in 2023.
Read more about our sponsorship opportunities, here: https://t.co/nIVsaDmPC5 https://t.co/wNB8fgbTR2
A big thank you to @LillyPadEU for continuing to support our activities! Lilly has opted for gold sponsorship of our activities in 2023.
Read more about our sponsorship opportunities, here: https://t.co/nIVsaD5eKx https://t.co/9HVJkk9HvR
.@TauRx presents top line data from its phase III LUCIDITY #clinicaltrial at #CTAD22, showing a sustained improvement in cognition over pre-treatment levels in participants with mild cognitive impairment (MCI) due to Alzheimer's disease
https://t.co/VJ1fWLWzuz
Otsuka Pharmaceutical and @Lundbeck presented data from three Phase 3 #clinicaltrials showing that #brexpiprazole significantly improved symptoms of agitation in people with #Alzheimer’s #dementia at #ctad22
https://t.co/HxA4RZLKDy
